CO
COCP.US Cocrystal Pharma Inc
- Market cap
- USD 18.9M
- P/E
- -
- P/B
- 18.45x
- ROE
- -1,046.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is COCP.US undervalued?
Graham numberThe Graham number of Cocrystal Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cocrystal Pharma Inc fundamental analysis
No fundamental analysis for Cocrystal Pharma Inc yet.
Cocrystal Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhi…
Full company profileCocrystal Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cocrystal Pharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 6.56M | 2.01M | 5.43M | 0.00 | 0.00 | 0.00 | 0.00 | 660K |
| Gross Profit | -201K | -101K | -50.0K | 2.56M | -4.02M | -8.79M | -12.4M | -15.2M | -12.5M | -5.06M | 660K |
| Operating Income | -106M | -8.26M | -62.9M | -48.4M | -9.59M | -14.2M | -38.8M | -18.6M | -17.9M | -9.02M | -11.1M |
| EBITDA | -106M | -7.39M | -62.5M | -2.21M | -9.43M | -14.0M | -17.7M | -21.0M | -17.4M | -8.46M | -10.9M |
| Net Income | -74.9M | -613K | -49.0M | -48.2M | -9.65M | -14.2M | -38.8M | -18.0M | -17.5M | -8.83M | -10.9M |
| EPS | -38 | -0.30 | -21 | -16 | -2.01 | -1.84 | -4.77 | -1.86 | -1.72 | -0.78 | -0.79 |
| Balance Sheet | |||||||||||
| Total Assets | 125M | 121M | 68.6M | 28.5M | 54.2M | 79.4M | 40.8M | 31.3M | 13.5M | 9.71M | 4.65M |
| Total Liabilities | 22.6M | 16.0M | 1.67M | 2.82M | 1.74M | 1.84M | 1.27M | 4.88M | 3.93M | 3.38M | 3.61M |
| Shareholders' Equity | 102M | 105M | 66.9M | 25.7M | 52.5M | 77.5M | 39.6M | 26.4M | 9.52M | 6.33M | 1.04M |
| Cash & Short-term Investments | 3.64M | 748K | 2.72M | 7.42M | 33.0M | 58.7M | 37.1M | 26.4M | 9.86M | 7.03M | 2.17M |
| Total Debt | - | 1.01M | 331K | 817K | 596K | 534K | 297K | 1.85M | 1.81M | 1.51M | 1.34M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.7M | -6.90M | -8.29M | -1.56M | -9.83M | -12.7M | -21.4M | -14.7M | -16.5M | -8.19M | -9.71M |
| Capital Expenditure | 51.0K | 40.0K | 28.0K | 145K | 240K | 52.0K | 74.0K | 118K | 8.00K | 12.0K | 0.00 |
| Free Cash Flow | -14.7M | -6.94M | -8.32M | -1.71M | -10.1M | -12.8M | -21.5M | -14.8M | -16.5M | -8.20M | -9.71M |
| Ratios | |||||||||||
| ROE | -73.2% | -0.6% | -73.3% | -187.4% | -18.4% | -18.3% | -98.2% | -68.2% | -183.8% | -139.5% | -1,046.6% |
| ROA | -60.0% | -0.5% | -71.5% | -168.8% | -17.8% | -17.9% | -95.1% | -57.5% | -130.1% | -90.9% | -235.0% |
| Net Profit Margin | - | - | - | -733.8% | -479.0% | -261.4% | - | - | - | - | -1,655.5% |
| Debt to Equity | - | 0.01x | 0.00x | 0.03x | 0.01x | 0.01x | 0.01x | 0.07x | 0.19x | 0.24x | 1.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cocrystal Pharma Inc dividends
Cocrystal Pharma Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Oct 11, 2022.
Who owns Cocrystal Pharma Inc
- Insiders 22.40%
- Institutions 5.99%
- Public & others 71.60%
- Shares outstanding 19.3M
- Free float 14.6M
Top funds holding COCP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 187K | 0.97% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 97.9K | 0.51% | +97.57% | Sep 2026 |
| Fidelity Series Total Market Index | 9.63K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 8.53K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.63K | 0.01% | 0.00% | Aug 2026 |
Top institutions holding COCP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 358K | 1.86% | +49.28% | Jun 2026 |
| Renaissance Technologies Corp | 180K | 0.93% | +44.95% | Jun 2026 |
| Two Sigma Investments LLC | 175K | 0.91% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 76.2K | 0.40% | -15.54% | Jun 2026 |
| BlackRock Inc | 73.7K | 0.38% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 45.1K | 0.23% | 0.00% | Jun 2026 |
| Neuberger Berman Group LLC | 31.9K | 0.17% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 29.3K | 0.15% | -18.56% | Jun 2026 |
| Jane Street Group LLC | 25.8K | 0.13% | +102.67% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 24.0K | 0.12% | 0.00% | Jun 2026 |
| State Street Corp | 20.5K | 0.11% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 20.3K | 0.11% | 0.00% | Jun 2026 |
| Parallel Advisors, LLC | 12.6K | 0.07% | 0.00% | Jun 2026 |
| Northern Trust Corp | 11.9K | 0.06% | 0.00% | Jun 2026 |
| Ground Swell Capital, LLC | 10.8K | 0.06% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 6.26K | 0.03% | -11.11% | Jun 2026 |
| UBS Group AG | 4.13K | 0.02% | -11.00% | Jun 2026 |
| Tower Research Capital LLC | 3.98K | 0.02% | -6.21% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 871.00 | 0.00% | -8.12% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 817.00 | 0.00% | 0.00% | Jun 2026 |
Cocrystal Pharma Inc company profile
- Company name
- Cocrystal Pharma Inc
- Ticker
- COCP.US
- Exchange
- USA Stocks
- Listed since
- May 19, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10
- Fiscal year end
- December
- Address
- 19805 North Creek Parkway, Bothell, WA, United States, 98011
- Phone
- 877 262 7123
- Website
- cocrystalpharma.com
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Cocrystal Pharma Inc management
4- Prof. Roger D. Kornberg Ph.D.Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board · born 1947
- Dr. Sam Lee Ph.D.Chief Scientific Officer, Co-Founder & President · born 1960
- Mr. James J. Martin CPA, M.B.A.CFO & Corporate Secretary · born 1967
- Mr. James R. Sapirstein M.B.A., R.Ph.Chief Executive Officer · born 1961